1. Wright NC, Looker AC, Saag KG, et al. The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J Bone Miner Res. 2014;29(11):2520-2526.
2. Bone Health and Osteoporosis Foundation. Fast Facts About Osteoporosis. Available at https://www.bonehealthandosteoporosis.org/wp-content/uploads/Fast-Facts-About-Osteoporosis-2.pdf. Last accessed October 14, 2024.
3. National Institute of Arthritis and Musculoskeletal and Skin Diseases. Bone Health and Osteoporosis: What It Means to You. Available at https://www.niams.nih.gov/health-topics/surgeon-generals-report-bone-health-and-osteoporosis-what-it-means-you. Last accessed October 14, 2024.
4. Bone Health and Osteoporosis Foundation. Are You at Risk? Available at https://www.bonehealthandosteoporosis.org/preventing-fractures/general-facts/bone-basics/are-you-at-risk/. Last accessed October 14, 2024.
5. Elam RE, Jackson NN, Machua W. Osteoporosis. Available at https://emedicine.medscape.com/article/330598-overview. Last accessed October 14, 2024.
6. Mauck KF, Clarke BL. Diagnosis, screening, prevention, and treatment of osteoporosis. Mayo Clin Proc. 2006;81(5):662-672.
7. Khoo BC, Brown K, Cann C, et al. Comparison of QCT-derived and DXA-derived areal bone mineral density and T scores. Osteoporos Int. 2009;20(9):1539-1545.
8. Link TM. Axial and peripheral QCT. In: Guglielmi G (ed). Osteoporosis and Bone Densitometry Measurements. New York, NY: Springer Heidelberg; 2013: 123-132.
9. Kraenzlin ME, Kraenzlin CA, Meier C, Giunta C, Steinmann B. Automated HPLC assay for urinary collagen cross-links: effect of age, menopause, and metabolic bone diseases. Clin Chem. 2008;54(9):1546-1553.
10. Qaseem A, Hicks LA, Etxeandia-Ikobaltzet I, Shamliyan T, Cooney TG. Pharmacologic treatment of primary osteoporosis or low bone mass to prevent fractures in adults: a living clinical guideline from the American College of Physicians. Ann Intern Med. 2023;172(2):224-238.
11. Bone Health and Osteoporosis Foundation. Prevention and Healthy Living. Available at https://www.bonehealthandosteoporosis.org/preventing-fractures/prevention/prevention-and-healthy-living/. Last accessed October 14, 2024.
12. Sandhu SK, Hampson G. The pathogenesis, diagnosis, investigation and management of osteoporosis. J Clin Pathol. 2011;64(12):1042-1050.
13. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333.
14. National Heart, Lung, and Blood Institute. Women's Health Initiative. Available at https://www.nhlbi.nih.gov/science/womens-health-initiative-whi. Last accessed October 14, 2024.
15. Consensus development conference: prophylaxis and treatment of osteoporosis. Am J Med. 1991;90(1):107-110.
16. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med. 1993;94(6):646-650.
17. World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994;843:1-129.
18. McClung MR. Assessing Fracture Risk in Individual Patients. Available at https://www.jwatch.org/wh200708300000001/2007/08/30/assessing-fracture-risk-individual-patients. Last accessed October 14, 2024.
19. World Health Organization. WHO Scientific Group on the Assessment of Osteoporosis at Primary Health Care Level. Available at https://frax.shef.ac.uk/FRAX/pdfs/WHO_Technical_Report.pdf. Last accessed October 14, 2024.
20. LeBoff MS, Greenspan SL, Insogna KL, et al. The clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int. 2022;33:2049-2102.
21. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285(6):785-795.
22. Bone Health and Osteoporosis Foundation. 54 Million Americans Affected by Osteoporosis and Low Bone Mass. Available at https://www.bonehealthandosteoporosis.org/news/54-million-americans-affected-by-osteoporosis-and-low-bone-mass/. Last accessed October 14, 2024.
23. Office of the Surgeon General. Bone Health and Osteoporosis: A Report of the Surgeon General. Available at https://www.ncbi.nlm.nih.gov/books/NBK45513. Last accessed October 14, 2024.
24. Dawson-Hughes B, Tosteson ANA, Melton LJ III, et al. Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int. 2008;19(4):449-458.
26. Jenkins MR, Denison AV. Smoking status as a predictor of hip fracture risk in postmenopausal women of Northwest Texas. Prev Chronic Dis. 2008;5(1):A09.
27. Theodorou SJ, Theodorou DJ, Sartoris DJ. Osteoporosis and fractures: the size of the problem. Hosp Med. 2003;64(2):87-91.
28. Hallberg I, Rosenqvist AM, Kartous L, Lofman O, Wahlstrom O, Toss G. Health-related quality of life after osteoporotic fractures. Osteoporos Int. 2004;15(10):834-841.
29. Randell AG, Nguyen TV, Bhalerao N, Silverman SL, Sambrook PN, Eisman JA. Deterioration in quality of life following hip fracture: a prospective study. Osteoporos Int. 2000;11(5):460-466.
30. Shevde NK, Bendixen AC, Dienger KM, Pike JW. Estrogens suppress RANK ligand-indiced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression. Proc Natl Acad Sci U S A. 2000;97(14):7829-7834.
31. International Osteoporosis Foundation. Who's At Risk? Available at https://www.osteoporosis.foundation/health-professionals/about-osteoporosis/risk-factors. Last accessed October 14, 2024.
32. Moayyeri A, Luben RN, Bingham SA, Welch AA, Wareham NJ, Khaw KT. Measured height loss predicts fractures in middle-aged and older men and women: the EPIC-Norfolk prospective population study. J Bone Miner Res. 2008;23(3):425-432.
33. International Society for Clinical Densitometry. ISCD Official Positions. Available at https://iscd.org/learn/official-positions/. Last accessed October 14, 2024.
35. The North American Menopause Society. Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause. 2010;17(1):25-54.
36. Camacho PM, Petak SM, Binkley N, Diab DL, Eldeiry LS, Farooki A, et al. American Association of Clinical Endrocrinologists/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis – 2020 update. Endocrine Pract. 2020;26(Suppl 1):1-46.
37. Bone Health and Osteoporosis Foundation. Evaluation of Bone Health/Bone Density Testing. Available at https://www.bonehealthandosteoporosis.org/patients/diagnosis-information/bone-density-examtesting/. Last accessed October 14, 2024.
38. Khaw KT, Reeve J, Luben R, et al. Prediction of total and hip fracture risk in men and women by quantitative ultrasound of the calcaneus: EPIC-Norfolk prospective population study. Lancet. 2004;363(9404):197-202.
39. 40. ACR Appropriateness Criteria: Osteoporosis and Bone Mineral Density. Reston, VA: American College of Radiology; 2016.
40. Yates AJ, Ross PD, Lydick E, Epstein RS. Radiographic absorptiometry in the diagnosis of osteoporosis. Am J Med. 1995;98(2A):41S-47S.
41. Nawaz Khan A, MacDonald S. Osteoporosis Imaging. Available at https://emedicine.medscape.com/article/393602-overview. Last accessed October 14, 2024.
42. Old JL, Calvert M. Vertebral compression fractures in the elderly. Am Fam Physician. 2004;69(1):111-116.
43. International Osteoporosis Foundation. Other Diagnostic Tools: Fracture Risk Assessment Tool (FRAX). Available at https://www.osteoporosis.foundation/health-professionals/diagnosis/other-diagnostic-tools. Last accessed October 14, 2024.
44. Rosen HN. Use of Biochemical Markers of Bone Turnover in Osteoporosis. Available at https://www.uptodate.com/contents/use-of-biochemical-markers-of-bone-turnover-in-osteoporosis/print#. Last accessed October 14, 2024.
45. Cadarette SM, Jaglal SB, Murray TM, et al. Evaluation of decision rules for referring women for bone densitometry by dual-energy x-ray absorptiometry. JAMA. 2001;286(1):57-63.
46. Crandall CJ. Risk assessment tools for osteoporosis screening in postmenopausal women: a systematic review. Curr Osteoporos Rep. 2015;13(5):287-301.
47. Richards JS, Lazzari AA, Teves Qualler DA, Desale S, Howard R, Kerr GS. Validation of the Osteoporosis Self-Assessment Tool in U.S. male veterans. J Clin Densitom. 2014;17(1):32-37.
48. Skedros JG, Sybrowsky CL, Stoddard GJ. The Osteoporosis Self-Assessment Screening Tool: a useful tool for the orthopaedic surgeon. J Bone Joint Surg Am. 2007;89(4):765-772.
49. Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists and American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis—2020 update. Endocr Pract. 2021;27(4):379-380.
50. U.S. Preventive Services Task Force. Osteoporosis to Prevent Fractures: Screening. Available at https://www.uspreventiveservicestask force.org/uspstf/draft-recommendation/osteoporosis-screening-prevent-fractures. Last accessed October 14, 2024.
51. Cheung AM, Feig DS, Kapral M, et al. Prevention of osteoporosis and osteoporotic fractures in postmenopausal women: recommendation statement from the Canadian Task Force on Preventive Health Care. CMAJ. 2004;170(11):1665-1667.
52. Morris CA, Cheng H, Cabral D, Solomon DH. Predictors of screening and treatment of osteoporosis: a structured review of the literature. Endocrinologist. 2004;14(2):70-75.
53. Smith MD, Ross W, Ahern MJ. Missing a therapeutic window of opportunity: an audit of patients attending a tertiary teaching hospital with potentially osteoporotic hip and wrist fractures. J Rheumatol. 2001;28(11):2504-2508.
54. Hayes BL, Curtis JR, Laster A, et al. Osteoporosis care in the United States after declines in reimbursements for DXA. J Clin Densitom. 2010;13(4):352-360.
55. McAdam-Marx C, Unni S, Ye X, Nelson S, Nickman NA. Effect of Medicare reimbursement reduction for imaging services on osteoporosis screening rates. J Am Geriatr Soc. 2012;60(3):511-516.
56. Kim SJ, Lee JH, Kim S, et al. Associations between the 2007 Medicare reimbursement reduction for bone mineral density testing and osteoporosis drug therapy patterns of female Medicare beneficiaries. Patient Prefer Adherence. 2014;8:909-915.
57. Yoo JW, Nakagawa S, Kim S. Effect of reimbursement reductions on bone mineral density testing for female Medicare beneficiaries.J Womens Health (Larchmt). 2012;21(11):1144-1148.
58. Licata AA. Diagnosing primary osteoporosis: it's more than a T-score. Cleve Clin J Med. 2006;73(5):473-476.
59. National Institutes of Health, Office of Dietary Supplements. Calcium. Available at https://ods.od.nih.gov/factsheets/Calcium-Consumer. Last accessed October 14, 2024.
60. National Institutes of Health. Office of Dietary Supplements. Vitamin D. Available at https://ods.od.nih.gov/factsheets/VitaminD-Consumer/. Last accessed October 14, 2024.
61. Al-Anazi AF, Qureshi VF, Javaid K, Qureshi S. Preventive effects of phytoestrogens against postmenopausal osteoporosis as compared to the available therapeutic choices: an overview. J Nat Sci Biol Med. 2011;2(2):154-163.
62. Reinwald S, Weaver CM. Soy isoflavones and bone health: a double-edge sword? J Nat Prod. 2006;69(3):450-459.
63. Johnson EB, Muto MG, Yanushpolsky EH, Mutter GL. Phytoestrogen supplementation and endometrial cancer. Obstet Gynecol. 2001;98(5 Pt 2):947-950.
64. Obermeyer WR, Musser SM, Betz JM, Casey RE, Pohland AE, Page SW. Chemical studies of phytoestrogens and related compounds in dietary supplements: flax and chaparral. Proc Soc Exp Biol Med. 1995;208(1):6-12.
65. Albertazzi P, Purdie D. The nature and utility of the phytoestrogens: a review of the evidence. Maturitas. 2002;42(3):173-185.
66. Geller SE, Studee L. Botanical and dietary supplements for menopausal symptoms: what works, what does not. J Womens Health (Larchmt). 2005;14(7):634-649.
67. Lagari VS, Levis S. Phytoestrogens in the prevention of postmenopausal bone loss. J Clin Densitom. 2013;6(4):445-449.
68. Medical News Today. What are Phytoestrogens? Benefits and Foods. Available at https://www.medicalnewstoday.com/articles/320630. Last accessed October 14, 2024.
69. Atkinson C, Compston JE, Day NE, Dowsett M, Bingham SA. The effects of phytoestrogen isoflavones on bone density in women: a double-blind, randomized, placebo-controlled study. Am J Clin Nutri. 2004;79(2):326-333.
70. Cook A, Pennington G. Phytoestrogen and multiple vitamin/mineral effects on bone mineral density in early postmenopausal women: a pilot study. J Womens Health Gend Based Med. 2002;11(1):53-60.
71. Zheng X, Lee SK, Chun OK. Soy isoflavones and osteoporotic bone loss: a review with an emphasis on modulation of bone remodeling. J Med Food. 2016;19(1):1-14.
72. Dede AD, Makras P, Anastasilakis AD. Investigational anabolic agents for the treatment of osteoporosis: an update on recent developments. Expert Opin Investig Drugs. 2017;26(10):1137-1144.
73. LexiComp Online. Available at http://online.lexi.com. Last accessed October 14, 2024.
74. U.S. Food and Drug Administration. FDA Approves New Treatment for Osteoporosis in Postmenopausal Women at High Risk of Fracture. Available at https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-osteoporosis-postmenopausal-women-high-risk-fracture#. Last accessed October 14, 2024.
75. Qaseem A, Forciea MA, McLean RM, et al for the Clinical Guidelines Committee of the American College of Physicians. Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2017;166(11):818-839.
76. Hulley S, Furberg C, Barrett-Connor E, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002;288(1):58-66.
77. U.S. Preventive Services Task Force. Hormone Therapy in Postmenopausal Persons: Primary Prevention of Chronic Conditions. Available at https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/menopausal-hormone-therapy-preventive-medication. Last accessed October 14, 2024.
78. Rey JR, Cervino EV, Rentero ML, Crespo EC, Alvaro AO, Casillas M. Raloxifene: mechanism of action, effects on bone tissue, and applicability in clinical traumatology practice. Open Orthop J. 2009;3:14-21.
79. Cranney A, Adachi JD. Benefit-risk assessment of raloxifene in postmenopausal osteoporosis. Drug Saf. 2005;28(8):721-730.
81. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. JAMA. 1999;281(23):2189-2197.
82. Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Eng J Med. 2006;355(2):125-137.
83. Cummings SR, Ettinger B, Delmas PD, et al. The effects of tibolone in older postmenopausal women. N Engl J Med. 2008;359(7):697-708.
84. European Medicines Agency. Conbriza. Available at https://www.ema.europa.eu/medicines/human/EPAR/conbriza. Last accessed October 14, 2024.
85. Silverman SL, Christiansen C, Genant HK, et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res. 2008;23(12):1923-1934.
86. Drugs@FDA. Label and Approval History: Duavee. Available at https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022247. Last accessed October 14, 2024.
87. Allen CS, Yeung JH, Vandermeer B, Homik J. Bisphosphonates for steroid-induced osteoporosis. Cochrane Database Syst Rev. 2016;10:CD001347.
88. U.S. Food and Drug Administration. [Archived Content]. Update of Safety Review Follow-Up to the October 1, 2007 Early Communication About the Ongoing Safety Review of Bisphosphonates. Available at https://wayback.archive-it.org/7993/20170112032108/http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm136201.htm. Last accessed October 14, 2024.
89. Rosen CJ, Hochberg MC, Bonnick SL, et al. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res. 2005;20:141-151.
90. Bonnick S, Saag KG, Kiel DP, et al. Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. J Clin Endocrinol Metab. 2006;91:2631-2637.
91. Rosen HN. Bisphosphonates Therapy for the Treatment of Osteoporosis. Available at https://www.uptodate.com/contents/bisphosphonate-therapy-for-the-treatment-of-osteoporosis. Last accessed October 14, 2024.
92. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA. 1999;282(14):1344-1352.
93. Byun JH, Jang S, Lee S, et al. The efficacy of bisphosphonates for prevention of osteoporotic fracture: an update meta-analysis. J Bone Metab. 2017;24(1):37-49.
94. Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-Term Extension (FLEX): a randomized trial. JAMA. 2006;296(24):2927-2938.
95. Schwartz AV, Bauer DC, Cummings SR, et al. Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J Bone Miner Res. 2010;25(5):976-982.
96. Bauer DC, Schwartz A, Palermo L, et al. Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study. JAMA Intern Med. 2014;174(7):1126-1134.
97. Ensrud KE, Barrett-Connor EL, Schwartz A, et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. J Bone Miner Res. 2004;19(8):1259-1269.
98. Tandon VR, Sharma S, Mahajan A. Bisphosphonate drug holidays: can we recommend currently? J Midlife Health. 2014;5(3):111-114.
99. McClung M. Controversies in osteoporosis management: concerns about bisphosphonates and when are "drug holidays" required?Clin Obstet Gynecol. 2013;56(4):743-748.
100. Diab DL, Watts NB. Use of drug holidays in women taking bisphosphonates. Menopause. 2014;21(2):195-197.
101. Black DM, Cummings SR, Karpf DB, et al. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 1996;348(9041):1535-1541.
102. Roux C, Binkley N, Boonen S, et al. Vitamin D status and bone mineral density changes during alendronate treatment in postmenopausal osteoporosis. Calcif Tissue Int. 2014;94(2):153-157.
103. Physician's Desk Reference. Available at http://www.pdr.net. Last accessed October 14, 2024.
104. Ascott-Evans BH, Guanabens N, Kivinen S, et al. Alendronate prevents loss of bone density associated with discontinuation of hormone replacement therapy. Arch Intern Med. 2003;163(7):789-794.
105. Bone HG, Greenspan SL, McKeever C, et al. Alendronate and estrogen effects in postmenopausal women with low bone mineral density. J Clin Endocrinol Metab. 2000;85(2):720-726.
106. Greenspan SL, Emkey RD, Bone HG, et al. Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2002;137(11):875-883.
107. Wasnich RD, Bagger YZ, Hosking DJ, et al. Changes in bone density and turnover after alendronate or estrogen withdrawal. Menopause. 2004;11(6 Pt 1):622-630.
108. Harris ST, Watts NB, Genank HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized control trial. JAMA. 1999;282(14):1344-1352.
109. McClung MR, Zanchetta JR, Racewicz A, et al. Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis: 2-year data. Osteoporos Int. 2013;24(1):293-299.
110. McClung MR, Lewiecki M, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006;354(8):821-831.
111. Lipton A, Steger GG, Figueroa J, et al. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol. 2007;25(28):4431-4437.
112. Daily Med. Denosumab. Available at https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=denosumab. Last accessed October 14, 2024.
113. National Cancer Institute. Denosumab. Available at https://www.cancer.gov/about-cancer/treatment/drugs/denosumab?redirect=true. Last accessed October 14, 2024.
115. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756-765.
116. Zhou Z, Chen C, Zhang J, et al. Safety of denosumab in postmenopausal women with osteoporosis or low bone mineral density: a meta-analysis. Int J Clin Exp Pathol. 2014;7(5):2113-2122.
117. Brown JP, Roux C, Ho PR, et al. Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate. Osteoporos Int. 2014;25(7):1953-1961.
118. Bilezikian JP, Lin CJF, Brown JP et al. Long-term denosumab treatment restores cortical bone loss and reduces fracture risk at the forearm and humerus: analyses from the FREEDOM Extension cross-over group. Osteoporos Int. 2019;30(9):1855–1864.
119. Papapoulos S, Lippuner K, RouxC, et al. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study. Osteoporos Int. 2015;26(12):2773–2783.
121. Cranney A, Welch V, Adachi JD, et al. Calcitonin for the treatment and prevention of corticosteroid-induced osteoporosis. Cochrane Database Syst Rev. 2000;(1):CD001983.
122. North American Menopause Society. Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society. Menopause. 2021;28(9):973-997.
123. Hodsman A, Papaioannou A, Cranney A. Clinical practice guidelines for the use of parathyroid hormone in the treatment of osteoporosis. CMAJ. 2006;175(1):48-51.
124. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434-1441.
125. Harsløf T, Langdahl BL. New horizons in osteoporosis therapies. Curr Opin Pharmacol. 2016;28:38-42.
126. Leder BZ. Parathyroid hormone and parathyroid hormone-related protein analogs in osteoporosis therapy. Curr Osteoporos Rep. 2017:
127. Pietrogrande L, Raimondo E. Abaloparatide for the treatment of postmenopausal osteoporosis. Drugs Today (Barc). 2018;54(5):293-303.
128. Miller PD, Hattersley G, Riis BJ, et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA. 2016;316(7):722-733.
129. Neuprez A, Hiligsmann M, Scholtissen S, Bruyere O, Reginster JY. Strontium ranelate: the first agent of a new therapeutic class in osteoporosis. Adv Ther. 2008;25(12):1235-1256.
130. Reginster JY, Deroisy R, Neuprez A, Hiligsmann M, Zegels B, Bruyere O. Strontium ranelate: new data on fracture prevention and mechanisms of action. Curr Osteoporos Rep. 2009;7(3):96-102.
131. O'Donnell S, Cranney A, Wells GA, Adachi JD, Reginster JY. Strontium ranelate for preventing and treating postmenopausal osteoporosis. Cochrane Database Syst Rev. 2006;(4):CD005326.
132. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med. 2004;350(5):459-468.
133. Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: treatment of peripheral osteoporosis (TROPOS) study. J Clin Endocrinol Metab. 2005;90(5):2816-2822.
134. Menunier PJ, Roux C, Ortolani S, et al. Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis. Osteoporos Int. 2009;20(10):1663-1673.
135. Reginster JY, Felsenberg D, Boonen S, et al. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: results of a five-year, randomized, placebo-controlled trial. Arthritis Rheum. 2008;58(6):1687-1695.
136. Reginster JY, Kaufman JM, Goemaere S, et al. Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis. Osteoporos Int. 2012;23(3):1115-1122.
1. Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis—2020 update. Endocr Pract. 2020;26(Suppl 1):1-46. Available at https://www.sciencedirect.com/science/article/pii/S1530891X20428277. Last accessed October 15, 2024.
2. U.S. Preventive Services Task Force, Curry SJ, Krist AH, et al. Screening for osteoporosis to prevent fractures: US Preventive Services Task Force recommendation statement. JAMA. 2018;319(24):2521-2531. Available at https://jamanetwork.com/journals/jama/fullarticle/2685995. Last accessed October 15, 2024.
3. Allen S, Forney-Gorman A, Homan M, Kearns A, Kramlinger A, Sauer M. Diagnosis and Treatment of Osteoporosis. Bloomington, MN: Institute for Clinical Systems Improvement; 2017. Available at https://www.icsi.org/wp-content/uploads/2019/01/Osteo.pdf. Last accessed October 15, 2024.
Mention of commercial products does not indicate endorsement.